Natural products in structure-assisted design of molecular cancer therapeutics

Current Pharmaceutical Design

Volumn 16, Issue 15, 2010, Pages 1718-1741

  Pfisterer, Petra H ^a   Wolber, Gerhard ^a   Efferth, Thomas ^b   Rollinger, Judith M ^a   Stuppner, Hermann ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cancer; Docking; Drug discovery; In silico techniques; Molecular modeling; Natural product; Phytochemicals; Virtual screening

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANACARDIC ACID; ANTINEOPLASTIC AGENT; BUTYROLACTONE; COMBRETASTATIN A1 PHOSPHATE; DEHYDRODIDEMNIN B; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; GELDANAMYCIN; GEMCITABINE; GENISTEIN; HEAT SHOCK PROTEIN 90; IDN 5390; IXABEPILONE; LIGAND; MAMMALIAN TARGET OF RAPAMYCIN; MOTESANIB; MYRICETIN; NATURAL PRODUCT; OMBRABULIN; PACLITAXEL; PICEATANNOL; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; QUERCETIN; RESVERATROL; SORAFENIB; STAUROSPORINE; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TEMSIROLIMUS; TIPIFARNIB; TOZASERTIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE SULFATE; VINFLUNINE; BIOLOGICAL PRODUCT; DRUG DERIVATIVE; PLANT MEDICINAL PRODUCT; RAPAMYCIN;

CANCER THERAPY; CLINICAL EVALUATION; COMPUTER AIDED DESIGN; CYTOTOXICITY; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; EPIGENETICS; HUMAN; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION; APOPTOSIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETIC EPIGENESIS; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL PRODUCTS; DRUG DESIGN; EPIGENESIS, GENETIC; HSP90 HEAT-SHOCK PROTEINS; MODELS, MOLECULAR; PLANT PREPARATIONS; SIROLIMUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78049511546     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161210791164027     Document Type: Review

References (243)

1. Harvey AL. Natural products in drug discovery. Drug Discov Today 2008; 13: 894-901.
2. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70: 461-477.
3. Butler MS. Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep 2008; 25: 475-516.
4. Cragg GM, Kingston DGI, Newman DJ. In: Cragg GM, Kingston DGI, Newman DJ, Eds. Anticancer agents from natural products. Boca Raton: Taylor & Francis Group 2005; pp. 1-3.
5. Feher M, Schmidt JM. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 2003; 43: 218-227.
6. Verdine GL. The combinatorial chemistry of nature. Nature 1996; 384: 11-13.
7. Kintzios SE, Barberaki MG. Plants and cancer. In: Kintzios SE, Barberaki MG, Eds. Plants that fight cancer. Boca Raton: CRC Press LLC 2004; pp. 15-34.
8. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68: 3077-3080.
9. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009; 59: 111-37.
10. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007; 12: 191-200.
11. Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol 2009; 5: 616-624.
12. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the chinese Thunder of God Vine, is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006; 66: 4758-4765.
13. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005; 26: 178-182.
14. Korcsmaros T, Szalay MS, Bode C, Kovacs IA, Csermely P. How to design multi-target drugs: target search options in cellularnetworks. Exp Opin Drug Discov 2007; 2: 799-808.
15. Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 2008; 105: 4826-4831.
16. Li XJ, Zhang HY. Western-medicine-validated anti-tumor agents and traditional Chinese medicine. Trends Mol Med 2008; 14: 1-2.
17. Li XJ, Zhang HY. Synergy in natural medicines: implications for drug discovery. Trends Pharmacol Sci 2008; 29: 331-332.
18. Rollinger JM. Accessing target information by virtual parallel screening - the impact on natural product research. Phytochem Lett 2009; 2: 53-58.
19. Ehrmann TM, Barlow DJ, Hylands PJ. Phytochemical informatics of traditional chinese medicine and therapeutic relevance. J Chem Inf Model 2007; 47: 2316-2334.
20. Scapin G. Structural biology in drug design: selective protein kinase inhibitors. Drug Discov Today 2002; 7: 601-611.
21. van Montfort RL, Workman P. Structure-based design of molecular cancer therapeutics. Trends Biotechnol 2009; 27: 315-28.
22. Drews J. Drug discovery: a historical perspective. Science 2000; 287: 1960-1964.
23. Rollinger JM, Langer T, Stuppner H. Integrated in silico tools for exploiting the natural products' bioactivity. Planta Med 2006; 72: 671-678.
24. Rollinger JM, Langer T, Stuppner H. Strategies for efficient lead structure discovery from natural products. Curr Med Chem 2006; 13: 1491-1507.
25. Wolber G, Seidel T, Bendix F, Langer T. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discov Today 2008; 13: 23-29.
26. Sun HM. Pharmacophore-based virtual screening. Curr Med Chem 2008; 15: 1018-1024.
27. Rollinger JM, Schuster D, Danzl B, Schwaiger S, Markt P, Schmidtke M, et al. In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens. Planta Med 2009; 75: 195-204.
28. Berman HM, Westbrook J, Feng Z, Gililand G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res 2000; 28: 235-242.
29. Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996; 261: 470-489.
30. Ewing TJA, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput-Aided Mol Des 2001; 15: 411-428.
31. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997; 267: 727-748.
32. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998; 19: 1639-1662.
33. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004; 47: 1750-1759.
34. Venkatachalam CM, Jiang X, Oldfield T, Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 2003; 21: 289-307.
35. Jain AN. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 2003; 46: 499-511.
36. Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, Lambert MH, et al. A critical assessment of docking programs and scoring functions. J Med Chem 2006; 49: 5912-5931.
37. Böhm HJ. LUDI - Rule-based automatic design of new substituents for enzyme-inhibitor leads. J Comput-Aided Mol Des 1992; 6: 593-606.
38. Vallat BK, Pillardy J, Elber R. A template-finding algorithm and a comprehensive benchmark for homology modeling of proteins. Proteins 2008; 72: 910-928.
39. Wolber G, Langer T. LigandScout: 3-d pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 2005; 45: 160-169.
40. Wolber G, Langer T. CombiGen: a novel software package for the rapid generation of virtual combinatorial libraries. Rat Approach Drug Design 2001: 390-399.
41. Tiikkainen P, Markt P, Wolber G, Kirchmair J, Distinto S, Poso A, et al. Critical comparison of virtual screening methods against the MUV data set. J Chem Inf Model 2009; 49: 2168-2178.
42. Chiang YK, Kuo CC, Wu YS, Chen CT, Coumar MS, Wu JS, et al. Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. J Med Chem 2009; 52: 4221-4233.
43. Martin YC, Bures MG, Danaher EA, DeLazzer J, Lico I, Pavlik PA. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J Comput-Aided Mol Des 1993; 7: 83-102.
44. Discovery Studio 2.1/Catalyst; available from Accelrys. San Diego, CA, USA. (www.accelrys.com).
45. PHASE; available from Schrodinger Inc, New York, NY, USA. (www.schrodinger.com).
46. Cottrell SJ, Gillet VJ, Taylor R. Incorporating partial matches within multiobjective pharmacophore identification. J Comput-Aided Mol Des 2006; 20: 735-749.
47. Wolber G, Dornhofer AA, Langer T. Efficient overlay of small organic molecules using 3D pharmacophores. J Comput-Aided Mol Des 2006; 20: 773-788.
48. Melville JL, Burke EK, Hirst JD. Machine learning in virtual screening. Comb Chem High Throughput Screen 2009; 12: 332-343.
49. Kirchmair J, Distinto S, Markt P, Schuster D, Spitzer GM, Liedl KR, et al. How to optimize shape-based virtual screening: choosing the right query and including chemical information. J Chem Inf Model 2009; 49: 678-692.
50. Davis AM, Teague SJ, Kleywegt GJ. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew Chem Int Ed Engl 2003; 42: 2718-2736.
51. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 1995; 80: 225-236.
52. Cohen P. Protein kinases--the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002; 1: 309-315.
53. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000; 69: 373-698.
54. Marsden BD, Knapp S. Doing more than just the structure-structural genomics in kinase drug discovery. Curr Opin Chem Biol 2008; 12: 40-45.
55. Kinnings SL, Jackson RM. Binding site similarity analysis for the functional classification of the protein kinase family. J Chem Inf Model 2009; 49: 318-329.
56. Rockey WM, Elcock AH. Structure selection for protein kinase docking and virtual screening: homology models or crystal structures? Curr Protein Pept Sci 2006; 7: 437-457.
57. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2: 358-364.
58. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
59. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002; 277: 46265-46272.
60. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 6652-6659.
61. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008; 105: 2070-2075.
62. Konkimalla VB, Suhas VL, Chandra NR, Gebhart E, Efferth T. Diagnosis and therapy of oral squamous cell carcinoma. Expert Rev Anticancer Ther 2007; 7: 317-329.
63. Zhu L, Xu X. Selective separation of active inhibitors of epidermal growth factor receptor from Caragana jubata by molecularly imprinted solid-phase extraction. J Chromatogr A 2003; 991: 151-158.
64. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262: 5592-5595.
65. Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997; 385: 602-609.
66. De Azevedo WF, Jr., Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 1996; 93: 2735-2740.
67. Traxler P, Green J, Mett H, Sequin U, Furet P. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem 1999; 42: 1018-1026.
68. Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997; 385: 595-602.
69. Breitenlechner CB, Kairies NA, Honold K, Scheiblich S, Koll H, Greiter E, et al. Crystal structures of active SRC kinase domain complexes. J Mol Biol 2005; 353: 222-231.
70. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000; 19: 5636-5642.
71. Lin LG, Xie H, Li HL, Tong LJ, Tang CP, Ke CQ, et al. Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening. J Med Chem 2008; 51: 4419-4429.
72. Granville CA, Memmott RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006; 12: 679-689.
73. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
74. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008; 26: 361-367.
75. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000; 6: 909-919.
76. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-5218.
77. Kuang RR, Qian F, Li Z, Wei DZ, Tang Y. Action mechanisms and structure-activity relationships of PI3Kgamma inhibitors on the enzyme: a molecular modeling study. Eur J Med Chem 2006; 41: 558-565.
78. Kuang RR, Qian F, Li Z, Wei DZ. Study on improving the selectivity of compounds that inhibit two PI3Ks (gamma and delta). J Mol Model 2006; 12: 445-452.
79. Zvelebil MJ, Waterfield MD, Shuttleworth SJ. Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors. Arch Biochem Biophys 2008; 477: 404-410.
80. Frederick R, Denny WA. Phosphoinositide-3-kinases (PI3Ks): combined comparative modeling and 3D-QSAR to rationalize the inhibition of p110alpha. J Chem Inf Model 2008; 48: 629-638.
81. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 2007; 318: 1744-1748.
82. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4: 937-947.
83. Rajalingam K, Schreck R, Rapp UR, Albert S. Ras oncogenes and their downstream targets. Biochim Biophys Acta 2007; 1773: 1177-1195.
84. Krengel U, Schlichting I, Scherer A, Schumann R, Frech M, John J, et al. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. Cell 1990; 62: 539-548.
85. Gibbs JB, Oliff A. Pharmaceutical research in molecular oncology. Cell 1994; 79: 193-198.
86. Park HW, Boduluri SR, Moomaw JF, Casey PJ, Beese LS. Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science 1997; 275: 1800-1804.
87. Stimmel JB, Deschenes RJ, Volker C, Stock J, Clarke S. Evidence for an S-farnesylcysteine methyl ester at the carboxyl terminus of the Saccharomyces cerevisiae RAS2 protein. Biochemistry 1990; 29: 9651-9659.
88. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438.
89. Pedretti A, Villa L, Vistoli G. Modeling of binding modes and inhibition mechanism of some natural ligands of farnesyl transferase using molecular docking. J Med Chem 2002; 45: 1460-1465.
90. Sung ND, Cheun YG, Kwon BM, Park HY, Kim CK. Modeling of inhibition mechanism of natural ligands to farnesyl protein transferase using molecular docking. Bull Korean Chem Soc 2003; 24: 1509-1511.
91. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004; 11: 1192-1197.
92. Lee KW, Kang NJ, Rogozin EA, Oh SM, Heo YS, Pugliese A, et al. The resveratrol analogue 3,5,3',4',5'-pentahydroxy-trans-stilbene inhibits cell transformation via MEK. Int J Cancer 2008; 123: 2487-2496.
93. Lee KW, Kang NJ, Rogozin EA, Kim HG, Cho YY, Bode AM, et al. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis 2007; 28: 1918-1927.
94. Kim JE, Kwon JY, Lee DE, Kang NJ, Heo YS, Lee KW, et al. MKK4 is a novel target for the inhibition of tumor necrosis factor-alpha-induced vascular endothelial growth factor expression by myricetin. Biochem Pharmacol 2009; 77: 412-421.
95. Darnell JE, Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
96. Quesnelle KM, Boehm AL, Grandis JR. STAT-mediated EGFR signaling in cancer. J Cell Biochem 2007; 102: 311-319.
97. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995; 269: 81-83.
98. Shuai K, Horvath CM, Huang LH, Qureshi SA, Cowburn D, Darnell JE, Jr. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994; 76: 821-828.
99. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE, Jr., Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 1998; 93: 827-839.
100. Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998; 394: 145-151.
101. Hao W, Hu Y, Niu C, Huang X, Chang CP, Gibbons J, et al. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening. Bioorg Med Chem Lett 2008; 18: 4988-4992.
102. Shakespeare WC. SH2 domain inhibition: a problem solved? Curr Opin Chem Biol 2001; 5: 409-415.
103. Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol 1999; 11: 490-496.
104. Song H, Wang R, Wang S, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005; 102: 4700-4705.
105. Li JJ, Li SA. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther 2006; 111: 974-984.
106. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8: 547-566.
107. Furet P, Meyer T, Mittl P, Fretz H. Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching. J Comput Aided Mol Des 2001; 15: 489-495.
108. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol 1996; 6: 393-397.
109. Brana MF, Garcia ML, Lopez B, de Pascual-Teresa B, Ramos A, Pozuelo JM, et al. Synthesis and biological evaluation of analogues of butyrolactone I and molecular model of its interaction with CDK2. Org Biomol Chem 2004; 2: 1864-1871.
110. Jessen BA, Lee L, Koudriakova T, Haines M, Lundgren K, Price S, et al. Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors. J Appl Toxicol 2007; 27: 133-142.
111. Saturno G, Pesenti M, Cavazzoli C, Rossi A, Giusti AM, Gierke B, et al. Expression of serine/threonine protein-kinases and related factors in normal monkey and human retinas: the mechanistic understanding of a CDK2 inhibitor induced retinal toxicity. Toxicol Pathol 2007; 35: 972-983.
112. Orzaez M, Gortat A, Mondragon L, Bachs O, Perez-Paya E. ATP-noncompetitive inhibitors of CDK-cyclin complexes. ChemMedChem 2009; 4: 19-24.
113. Andrews MJ, Kontopidis G, McInnes C, Plater A, Innes L, Cowan A, et al. REPLACE: a strategy for iterative design of cyclin- binding groove inhibitors. ChemBioChem 2006; 7: 1909-1915.
114. Pollard JR, Mortimore M. Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem 2009; 52: 2629-2651.
115. Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N, et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005; 65: 2899-2905.
116. Tao Y, Zhang P, Frascogna V, Lecluse Y, Auperin A, Bourhis J, et al. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 2007; 97: 1664-1672.
117. Kim KW, Mutter RW, Willey CD, Subhawong TK, Shinohara ET, Albert JM, et al. Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. Int J Radiat Oncol Biol Phys 2007; 67: 1519-1525.
118. Tsuno T, Natsume A, Katsumata S, Mizuno M, Fujita M, Osawa H, et al. Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells. J Neurooncol 2007; 83: 249-258.
119. Kishore AH, Vedamurthy BM, Mantelingu K, Agrawal S, Reddy BA, Roy S, et al. Specific small-molecule activator of Aurora kinase A induces autophosphorylation in a cell-free system. J Med Chem 2008; 51: 792-797.
120. Fu DH, Jiang W, Zheng JT, Zhao GY, Li Y, Yi H, et al. Jadomycin B, an Aurora-B kinase inhibitor discovered through virtual screening. Mol Cancer Ther 2008; 7: 2386-2393.
121. Cheetham GM, Charlton PA, Golec JM, Pollard JR. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 2007; 251: 323-329.
122. Sessa F, Mapelli M, Ciferri C, Tarricone C, Areces LB, Schneider TR, et al. Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. Mol Cell 2005; 18: 379-391.
123. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
124. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
125. Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, et al. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 2003; 17: 52-59.
126. Biscardi M, Caporale R, Balestri F, Gavazzi S, Jimeno J, Grossi A. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Ann Oncol 2005; 16: 1667-1674.
127. Cardenas F, Caba JM, Feliz M, Lloyd-Williams P, Giralt E. Analysis of conformational equilibria in aplidine using selective excitation 2D NMR spectroscopy and molecular mechanics/ dynamics calculations. J Org Chem 2003; 68: 9554-9562.
128. Cardenas F, Thormann M, Feliz M, Caba JM, Lloyd-Williams P, Giralt E. Conformational analysis of dehydrodidemnin B (aplidine) by NMR spectroscopy and molecular mechanics/dynamics calculations. J Org Chem 2001; 66: 4580-4584.
129. Stahl P, Kissau L, Mazitschek R, Giannis A, Waldmann H. Natural product derived receptor tyrosine kinase inhibitors: identification of IGF1R, Tie-2, and VEGFR-3 inhibitors. Angew Chem Int Ed 2002; 41: 1174-1178.
130. Korhonen J, Partanen J, Armstrong E, Vaahtokari A, Elenius K, Jalkanen M, et al. Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. Blood 1992; 80: 2548-2555.
131. Shewchuk LM, Hassell AM, Ellis B, Holmes WD, Davis R, Horne EL, et al. Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure 2000; 8: 1105-1113.
132. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423-435.
133. Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009; 15: 2594-2601.
134. Liu J, Towle MJ, Cheng H, Saxton P, Reardon C, Wu J, et al. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res 2007; 27: 1509-1518.
135. Taraboletti G, Micheletti G, Rieppi M, Poli M, Turatto M, Rossi C, et al. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res 2002; 8: 1182-1188.
136. Petrangolini G, Cassinelli G, Pratesi G, Tortoreto M, Favini E, Supino R, et al. Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft. Br J Cancer 2004; 90: 1464-1468.
137. Löwe J, Li H, Downing KH, Nogales E. Refined structure of alpha beta-tubulin at 3.5 A resolution. J Mol Biol 2001; 313: 1045-1057.
138. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. Science 2004; 305: 866-869.
139. Canales A, Matesanz R, Gardner NM, Andreu JM, Paterson I, Diaz JF, et al. The bound conformation of microtubule-stabilizing agents: NMR insights into the bioactive 3D structure of discodermolide and dictyostatin. Chem Eur J 2008; 14: 7557-7569.
140. Jiang Y, Alcaraz AA, Chen JM, Kobayashi H, Lu YJ, Snyder JP. Diastereomers of dibromo-7-epi-10-deacetylcephalomannine: crowded and cytotoxic taxanes exhibit halogen bonds. J Med Chem 2006; 49: 1891-1899.
141. Hutt OE, Reddy BS, Nair SK, Reiff EA, Henri JT, Greiner JF, et al. Total synthesis and evaluation of C25-benzyloxyepothilone C for tubulin assembly and cytotoxicity against MCF-7 breast cancer cells. Bioorg Med Chem Lett 2008; 18: 4904-4906.
142. Huzil JT, Chik JK, Slysz GW, Freedman H, Tuszynski J, Taylor RE, et al. A unique mode of microtubule stabilization induced by peloruside A. J Mol Biol 2008; 378: 1016-1030.
143. Yuan W, Luan LB, Li YN. CoMFA 3D-QSAR analysis of epothilones based on docking conformation and alignment. Chin J Chem 2007; 25: 453-460.
144. Pineda O, Farras J, Maccari L, Manetti F, Botta M, Vilarrasa J. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine. Bioorg Med Chem Lett 2004; 14: 4825-4829.
145. Paterson I, Menche D, Britton R, Hakansson AE, Silva-Martinez MA. Conformational studies and solution structure of laulimalide and simplified analogues using NMR spectroscopy and molecular modeling. Tetrahedron Lett 2005; 46: 3677-3682.
146. Magnani M, Ortuso F, Soro S, Alcaro S, Tramontano A, Botta M. The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies. FEBS J 2006; 273: 3301-3310.
147. Mitra A, Sept D. Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin. Biochemistry 2004; 43: 13955-13962.
148. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004; 428: 198-202.
149. Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA, et al. Structural basis for the regulation of tubulin by vinblastine. Nature 2005; 435: 519-522.
150. Romagnoli R, Baraldi PG, Pavani MG, Tabrizi MA, Preti D, Fruttarolo F, et al. Synthesis and biological evaluation of 2-amino-3-(3',4',5'-trimethoxybenzoyl)-5-aryl thiophenes as a new class of potent antitubulin agents. J Med Chem 2006; 49: 3906-3915.
151. Zhang Q, Peng Y, Wang XI, Keenan SM, Arora S, Welsh WJ. Highly potent triazole-based tubulin polymerization inhibitors. J Med Chem 2007; 50: 749-754.
152. Bellina F, Cauteruccio S, Monti S, Rossi R. Novel imidazole-based combretastatin A-4 analogues: evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin. Bioorg Med Chem Lett 2006; 16: 5757-5762.
153. Bonezzi K, Taraboletti G, Borsotti P, Bellina F, Rossi R, Giavazzi R. Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles. J Med Chem 2009; 52: 7906-7910.
154. Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, Day BW, et al. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem 2005; 48: 6107-6116.
155. Kim TY, Bang YJ, Robertson KD. Histone deacetylase inhibitors for cancer therapy. Epigenetics 2006; 1: 14-23.
156. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107.
157. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001; 61: 1327-1333.
158. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63: 7291-7300.
159. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001; 61: 7025-7029.
160. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001; 20: 3139-3155.
161. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyl-transferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003; 63: 7563-7570.
162. O'Gara M, Roberts RJ, Cheng X. A structural basis for the preferential binding of hemimethylated DNA by HhaI DNA methyltransferase. J Mol Biol 1996; 263: 597-5606.
163. Yamada H, Sugimura H, Tsuneyoshi T. Suppressive effect of epigallocatechin gallate (EGCG) on DNA methylation in mice: detection by methylation sensitive restriction endonuclease digestion and PCR. J Food Agric Environ 2005; 3: 73-76.
164. Lee WJ, Shim JY, Zhu BT. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol 2005; 68: 1018-1030.
165. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004; 12: 1325-1334.
166. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401: 188-193.
167. Massa S, Mai A, Sbardella G, Esposito M, Ragno R, Loidl P, et al. 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. J Med Chem 2001; 44: 2069-2072.
168. Mai A, Massa S, Ragno R, Esposito M, Sbardella G, Nocca G, et al. Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. J Med Chem 2002; 45: 1778-1784.
169. Mai A, Massa S, Ragno R, Cerbara I, Jesacher F, Loidl P, et al. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. J Med Chem 2003; 46: 512-524.
170. Ragno R, Mai A, Massa S, Cerbara I, Valente S, Bottoni P, et al. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. J Med Chem 2004; 47: 1351-1359.
171. Wang DF, Helquist P, Wiech NL, Wiest O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J Med Chem 2005; 48: 6936-6947.
172. Schäfer S, Saunders L, Eliseeva E, Velena A, Jung M, Schwienhorst A, et al. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorg Med Chem 2008; 16: 2011-2033.
173. Schäfer S, Saunders L, Schlimme S, Valkov V, Wagner JM, Kratz F, et al. Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors. ChemMedChem 2009; 4: 283-290.
174. Maulucci N, Chini MG, Di Micco S, Izzo I, Cafaro E, Russo A, et al. Molecular insights into azumamide E histone deacetylases inhibitory activity. J Am Chem Soc 2007; 129: 3007-3112.
175. Wen S, Carey KL, Nakao Y, Fusetani N, Packham G, Ganesan A. Total synthesis of azumamide A and azumamide E, evaluation as histone deacetylase inhibitors, and design of a more potent analogue. Org Lett 2007; 9: 1105-1108.
176. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008; 410: 439-453.
177. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407-410.
178. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997; 90: 65-75.
179. Chene P. ATPases as drug targets: learning from their structure. Nat Rev Drug Discov 2002; 1: 665-673.
180. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997; 89: 239-250.
181. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999; 42: 260-266.
182. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 2001; 8: 289-299.
183. Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 2009; 17: 2225-2235.
184. Wright L, Barril X, Dymock B, Sheridan L, Surgenor A, Beswick M, et al. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem Biol 2004; 11: 775-785.
185. Barril X, Brough P, Drysdale M, Hubbard RE, Massey A, Surgenor A, et al. Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005; 15: 5187-5191.
186. Cheung KM, Matthews TP, James K, Rowlands MG, Boxall KJ, Sharp SY, et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005; 15: 3338-3343.
187. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008; 68: 2850-2860.
188. Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, et al. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 2007; 99: 949-9461.
189. Lauria A, Ippolito M, Almerico AM. Inside the Hsp90 inhibitors binding mode through induced fit docking. J Mol Graph 2009; 27: 712-722.
190. Barril X, Morley SD. Unveiling the full potential of flexible receptor docking using multiple crystallographic structures. J Med Chem 2005; 48: 4432-4443.
191. Scheufler C, Brinker A, Bourenkov G, Pegoraro S, Moroder L, Bartunik H, et al. Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multicha-perone machine. Cell 2000; 101: 199-210.
192. Zhang M, Windheim M, Roe SM, Peggie M, Cohen P, Prodromou C, et al. Chaperoned ubiquitylation--crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex. Mol Cell 2005; 20: 525-538.
193. Meyer P, Prodromou C, Liao C, Hu B, Roe SM, Vaughan CK, et al. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J 2004; 23: 511-519.
194. Roe SM, Ali MM, Meyer P, Vaughan CK, Panaretou B, Piper PW, et al. The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 2004; 116: 87-98.
195. Westerheide SD, Bosman JD, Mbadugha BN, Kawahara TL, Matsumoto G, Kim S, et al. Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 2004; 279: 56053-56060.
196. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006; 10: 321-330.
197. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008; 7: 162-170.
198. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
199. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
200. Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004; 1644: 83-94.
201. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of Bcl-xL can confer a multidrug resistance phenotype. Blood 1995; 86: 1903-1910.
202. Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, et al. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 1997; 57: 62-67.
203. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381: 335-341.
204. Petros AM, Medek A, Nettesheim DG, Kim DH, Yoon HS, Swift K, et al. Solution structure of the antiapoptotic protein Bcl-2. Proc Natl Acad Sci USA 2001; 98: 3012-3017.
205. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275: 983-986.
206. Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001; 44: 4313-4324.
207. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97: 7124-7129.
208. Juin P, Geneste O, Raimbaud E, Hickman JA. Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochim Biophys Acta 2004; 1644: 251-260.
209. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J, et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001; 3: 183-191.
210. Wang S, Yang D. Inventors; small molecule antagonists of Bcl-2 family proteins. US patent 20030008924, 2002.
211. Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006; 49: 6139-6142.
212. Wang Z, Song W, Aboukameel A, Mohammad M, Wang G, Banerjee S, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer 2008; 123: 958-966.
213. Wang Z, Azmi AS, Ahmad A, Banerjee S, Wang S, Sarkar FH, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res 2009; 69: 2757-2765.
214. Ashimori N, Zeitlin BD, Zhang Z, Warner K, Turkienicz IM, Spalding AC, et al. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol Cancer Ther 2009; 8: 893-903.
215. Tang G, Ding K, Nikolovska-Coleska Z, Yang CY, Qiu S, Shangary S, et al. Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins. J Med Chem 2007; 50: 3163-3166.
216. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, Huang DC, et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci USA 2007; 104: 6217-6222.
217. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003; 46: 4259-4264.
218. Qiu J, Levin LR, Buck J, Reidenberg MM. Different pathways of cell killing by gossypol enantiomers. Exp Biol Med 2002; 227: 398-401.
219. Abou-Karam M, Shier WT. Inhibition of oncogene product enzyme activity as an approach to cancer chemoprevention. Tyrosine-specific protein kinase inhibition by purpurogallin from Quercus sp. nutgall. Phytother Res 1999; 13: 337-340.
220. Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res 2003; 63: 8118-81121.
221. Lang M, Henson R, Braconi C, Patel T. Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangio-carcinoma cells. Liver Int 2009; 29: 670-677.
222. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803.
223. Nomura T, Mimata H, Takeuchi Y, Yamamoto H, Miyamoto E, Nomura Y. The X-linked inhibitor of apoptosis protein inhibits taxol-induced apoptosis in LNCaP cells. Urol Res 2003; 31: 37-44.
224. Holcik M, Yeh C, Korneluk RG, Chow T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 2000; 19: 4174-4177.
225. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
226. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
227. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000; 408: 1008-1012.
228. Liu Z, Sun C, Olejniczak ET, Meadows RP, Betz SF, Oost T, et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000; 408: 1004-1008.
229. Nikolovska-Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller PP, et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 2004; 47: 2430-2440.
230. Danquah M, Li F, Duke CB, 3rd, Miller DD, Mahato RI. Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm Res 2009; 26: 2081-2092.
231. Dai Y, Qiao L, Chan KW, Yang M, Ye J, Ma J, et al. Peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of Embelin on colon carcinogenesis. Cancer Res 2009; 69: 4776-4783.
232. Chen J, Nikolovska-Coleska Z, Wang G, Qiu S, Wang S. Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. Bioorg Med Chem Lett 2006; 16: 5805-5808.
233. Sun H, Nikolovska-Coleska Z, Yang CY, Xu L, Liu M, Tomita Y, et al. Structure-based design of potent, conformationally constrained Smac mimetics. J Am Chem Soc 2004; 126: 16686-16687.
234. Sun H, Nikolovska-Coleska Z, Chen J, Yang CY, Tomita Y, Pan H, et al. Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. Bioorg Med Chem Lett 2005; 15: 793-797.
235. Huang JW, Zhang Z, Wu B, Cellitti JF, Zhang X, Dahl R, et al. Fragment-based design of small molecule X-linked inhibitor of apoptosis protein inhibitors. J Med Chem 2008; 51: 7111-7118.
236. Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL, et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004; 47: 4417-4426.
237. Sun H, Stuckey JA, Nikolovska-Coleska Z, Qin D, Meagher JL, Qiu S, et al. Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). J Med Chem 2008; 51: 7169-7180.
238. Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW, et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell 2001; 104: 791-800.
239. Chai J, Shiozaki E, Srinivasula SM, Wu Q, Dataa P, Alnemri ES, et al. Structural basis of caspase-7 inhibition by XIAP. Cell 2001; 104: 769-780.
240. Huang Y, Park YC, Rich RL, Segal D, Myszka DG, Wu H. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 2001; 104: 781-790.
241. Gao Z, Tian Y, Wang J, Yin Q, Wu H, Li YM, et al. A dimeric Smac/diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo. J Biol Chem 2007; 282: 3018-3027.
242. Sun H, Nikolovska-Coleska Z, Lu J, Meagher JL, Yang CY, Qiu S, et al. Design, synthesis, and characterization of a potent, nonpep-tide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc 2007; 129: 15279-15294.
243. Rollinger JM, Stuppner H, Langer T. Virtual screening for the discovery of bioactive natural products. In: Peterson F, Amstutz R, Eds. Natural Compounds as Drugs. Basel, Switzerland: Birkhäuser Verlag 2008; Vol. 1: pp. 212-249.